European Plant Problems Stalls Nabriva’s Antibiotic Approval

Drug Industry Daily
A A
Problems in one of Nabriva’s subcontracting plants have stalled the FDA’s review of the company’s proposed IV antibiotic Contepo.

To View This Article:

Login

Subscribe To Drug Industry Daily